Barclays analyst Emily Field has reiterated an 'Equal-Weight' rating on Amgen (AMGN) while increasing its price target from $360 to $380. This indicates a slightly more optimistic outlook on the stock's valuation by the analyst, though not a change in the overall investment recommendation.
Barclays analyst Emily Field maintained an 'Equal-Weight' rating on Amgen but raised the price target from $360 to $380. This action signals a modest increase in the analyst's valuation of Amgen, suggesting a slightly more favorable view on the stock's potential. While the 'Equal-Weight' rating implies the stock is expected to perform in line with the broader market, the higher price target could provide a minor positive sentiment boost for AMGN in the short term. For traders, this indicates a potential for slight upward movement, but it's not a strong buy signal, rather a confirmation of current valuation trends with a modest upside adjustment.